Physician profile
Caleb J Smith
NPI 1891284030
$2,219.50
in general payments reported to CMS, 2019-2025
36 companies · $1,782 in 2025
The $1,782 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.70 · 2022: $15.27 · 2023: $23.98 · 2024: $331 · 2025: $1,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,711 · Education: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.35 |
| Education | $426.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $190.18 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $190.18 | 2025 | Opdualag, Opdivo |
| Novartis Pharmaceuticals Corporation | $163.93 | 2024-2025 | |
| Lilly USA, LLC | $149.01 | 2025 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $142.87 | 2025 | Trodelvy |
| Janssen Biotech, INC. | $128.01 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Novo Nordisk INC | $116.64 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Seagen INC. | $99.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $94.84 | 2024-2025 | Enhertu |
| Glaxosmithkline, LLC. | $81.53 | 2024-2025 | Ojjaara, Jemperli |
| Daiichi Sankyo INC. | $79.64 | 2024-2025 | Enhertu |
| Genentech USA, INC. | $58.29 | 2024-2025 | Itovebi, Tecentriq, Phesgo |
| Celgene Corporation | $56.37 | 2025 | Reblozyl, Breyanzi |
| Incyte Corporation | $51.48 | 2025 | Jakafi, Niktimvo, Monjuvi |
| Genmab U.S., INC. | $43.51 | 2025 | Tivdak |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $42.05 | 2025 | Carvykti |
| Octapharma USA, INC. | $42.03 | 2025 | Octagam Immune Globulin (Human) |
| Servier Pharmaceuticals LLC | $39.77 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.69 | 2025 | Iclusig |
| Kite Pharma, INC. | $34.72 | 2025 | Yescarta |
| Genzyme Corporation | $34.57 | 2024-2025 | |
| Exelixis INC. | $33.77 | 2025 | Cabometyx |
| Taiho Oncology, INC. | $31.59 | 2025 | |
| Blueprint Medicines Corporation | $27.00 | 2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $24.78 | 2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $23.94 | 2024 | |
| Merck Sharp & Dohme LLC | $23.43 | 2025 | Keytruda |
| Beone Medicines USA, INC. | $22.59 | 2025 | Tevimbra |
| Caris Mpi, INC. | $22.57 | 2025 | Mi Cancer Seek |
| Puma Biotechnology, INC. | $22.33 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.20 | 2025 | |
| Immunocore Limited | $21.30 | 2025 | Kimmtrak |
| Adc Therapeutics America, INC. | $19.68 | 2025 | |
| Eisai INC. | $16.74 | 2025 | |
| Pfizer INC. | $15.83 | 2024 | |
| Jazz Pharmaceuticals INC. | $15.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.